BioDelivery Sciences International (BDSI) Stock Price, News & Analysis

Company Overview

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.

Key Stats

• Today's Range: $5.59 to $5.60
• 50-Day Range: $5.54 to $5.60
• 52-Week Range: $2.50 to $5.62
• Volume: 2.09 million shs
• Average Volume: 3.34 million shs
• Market Capitalization: $577.05 million
• P/E Ratio: 6.74
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioDelivery Sciences International Stock Analysis - MarketRank™

BioDelivery Sciences International scored higher than 38% of companies evaluated by MarketBeat, and ranked 738th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioDelivery Sciences International.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 73.68%

Earnings Growth

Earnings for BioDelivery Sciences International are expected to grow by 73.68% in the coming year, from $0.38 to $0.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioDelivery Sciences International is 6.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.04.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioDelivery Sciences International is 6.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.55.

Price to Book Value per Share Ratio

BioDelivery Sciences International has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BDSI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioDelivery Sciences International does not currently pay a dividend.

Dividend Growth

BioDelivery Sciences International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.18

Short Interest

There is no current short interest data available for BDSI.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioDelivery Sciences International this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioDelivery Sciences International insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.98% of the stock of BioDelivery Sciences International is held by insiders.

Percentage Held by Institutions

64.40% of the stock of BioDelivery Sciences International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BDSI Stock Analysis - Frequently Asked Questions

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) released its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported $0.07 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.01. The specialty pharmaceutical company had revenue of $41.09 million for the quarter, compared to the consensus estimate of $42.05 million. BioDelivery Sciences International had a trailing twelve-month return on equity of 21.25% and a net margin of 50.90%.

What other stocks do shareholders of BioDelivery Sciences International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BioDelivery Sciences International investors own include NVIDIA (NVDA), Bristol Myers Squibb (BMY), TG Therapeutics (TGTX), Meta Platforms (META), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 11/02/2021
• Today: 9/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BDSI
• CIK: 1103021
• Web: www.bdsi.com
• Phone: (919) 582-9050
• Fax: 919-582-9051
• Employees: 200
• Year Founded: 1997

Profitability

• EPS (Trailing Twelve Months): $0.83
• Trailing P/E Ratio: 6.74
• Forward P/E Ratio: 14.71
• P/E Growth: N/A
• Net Income: $84.86 million
• Net Margins: 50.90%
• Pretax Margin: 17.77%
• Return on Equity: 21.25%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 2.45
• Quick Ratio: 2.17

Sales & Book Value

• Annual Sales: $166.70 million
• Price / Sales: 3.46
• Cash Flow: $0.36 per share
• Price / Cash Flow: 15.42
• Book Value: $1.90 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 103,229,000
• Free Float: 92,927,000
• Market Cap: $577.05 million
• Optionable: Optionable
• Beta: 0.56